Allarity Therapeutics Inc(ALLR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.79 | Insider Own | 5.01% | Shs Outstand | 15.9M | Perf Week | 2.09% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | -7.5% | Insider Trans | - | Shs Float | 15.1M | Perf Month | -30.61% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.21 | Inst Own | 8.05% | Short Float | 0.74% | Perf Quarter | -15.06% |
| Income | -0.01B | P/S | 46.11 | EPS this Y | -2.56% | Inst Trans | 2.2% | Short Ratio | 1.13 | Perf Half Y | -15.06% |
| Sales | 0.00B | P/B | 4.43 | EPS next 5Y | - | ROA | -46.26% | Short Interest | 0.11M | Perf YTD | -8.77% |
| Book/sh | 0.22 | P/C | 0.58 | EPS past 3/5Y | 99.25% 94.6% | ROE | -157.09% | 52W High | -46.44% ($1.84) | Perf Year | -40.28% |
| Cash/sh | 1.7 | P/FCF | - | Sales past 3/5Y | - | ROIC | -348.81% | 52W Low | 28.18% ($0.77) | Perf 3Y | -99.76% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 91.38% | Gross Margin | 100% | Volatility(W/M) | 6.24% 8.65% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 32.31 | Sales Y/Y TTM | - | Oper. Margin | -3128.99% | ATR (14) | 0.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.11 | EPS Q/Q | -43.34% | Profit Margin | -3575.07% | RSI (14) | 34.28 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.11 | Sales Q/Q | - | SMA20 | -10.53% ($1.11) | Beta | 0.58 | Target Price | $11 |
| Payout | - | Debt/Eq | 6.3 | Earnings | 2026/8/14 | SMA50 | -21.35% ($1.26) | Rel Volume | 0.47 | Prev Close | $1 |
| Employees | 8 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 16% - | SMA200 | -20.29% ($1.24) | Avg Volume(3M) | 0.10M | Price | $0.99 |
| IPO | 2021/12/21 | Option/Short | No/Yes | Trades | 299 | Volume | 46,338 | Change | -1.47% |
A tiny biotech in Phase 2 clinical trials developing stenoparib (2X-121), a dual-target (PARP/WNT) anticancer drug aimed at hard-to-treat cancers such as ovarian cancer and small-cell lung cancer. The company also operates the DRP® companion diagnostics platform, which uses gene expression profiling to identify patients likely to respond, positioning it as a precision oncology company.
Over the past 1 year, on the lower side
46% below its 1-year high.
Traded less than usual That is 47% of its average volume.
ALLR has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -2.6% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $4,611. Peers typically go for $1,247.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -99.8%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 8.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #481 of 592 in the industry
Based on market cap of $16M.
DARE#478 Dare Bioscience Inc $16M PER - 
BCDA#479 BioCardia Inc $16M PER - 
NCEL#480 NewcelX Ltd $16M PER - ALLR#481 Allarity Therapeutics Inc $16M PER - 
NIKI#482 Niki BioSolutions Inc $15M PER - 
FAQ
What kind of company is ALLR?
ALLR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ALLR?
The market cap of ALLR is approximately $16M, ranking 5,345 within its sector.
What is the 52-week high and low for ALLR?
ALLR has recorded a 52-week high of $1.84 and a low of $0.77.
